



Tfw

APPLICANT(s): CUBERES ALTISEN et al.  
SERIAL NO.: 10/809,534 ART UNIT:  
FILING DATE: 3/19/04 EXAMINER:  
TITLE: SUBSTITUTED PYRAZOLINE COMPOUNDS, THEIR  
PREPARATION AND USE AS MEDICAMENTS  
ATTORNEY  
DOCKET NO.: 785-011730-US (PAR)

Commissioner of Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT  
(37 C.F.R. §1.97(b)(3))**

Sir:

This information disclosure statement is being filed before the mailing of a first Office Action on the merits.

The following information is being disclosed to the Patent and Trademark Office as information that may be material to the examination of the above-identified patent application. Applicants' Attorney is aware of the following references:

WO 00/76503 A1

"Health Aspects of Cannabis", Leo E. Hollister

"Chemistry and pharmacology of cannabis", Renu Seth et al., 1991,  
23 pages

"Potential Role of Cannabinoids for Therapy of Neurological Disorders", Consroe and Sandyk, 1992, 33 pages

"New Way for the Preparation of 4-Phenyl-2-Oxobutyric Acid Ethyl Ester", V. Slavinska et al.

"A Straightforward Route to E- $\gamma$ -Aryl- $\alpha$ -oxobutenic Esters by One-step Acid-catalysed Crotonisation of Pyruvates", Gilles Dujardin, et al.

"Synthese des 5-[(Acetylhydrazono)-(4-chlorphenyl)-methyl]thiophen-2-yl-esters der Trifluormethansulfonsäure", Alfons Pascual

"Regioselective Friedel-Crafts Acylation with Unsymmetrically Substituted Furandicarboxylic Acid Anhydride and Furan Acid Chloride: Syntheses of 4-Substituted 3-Arylcarbonyl-2-Phenylfuran and 3-Substituted 4-Arylcarbonyl-2-Phenylfuran", Shrong-Shi Lin, et al.

"Friedel-Crafts Acylations with Little or No Catalyst", D.E. Pearson, et al.

"Rational Syntheses of Porphyrins Bearing up to Four Different Meso Substituents", Poliseti Dharma Rao, et al.

"Pharmacological Effects of Hoe 249: A New Potential Antidepressant", Hans Georg Alperman, et al.

"Anticonvulsive Properties of Cinnarizine and Flunarizine in Rats and Mice", L.K. C. Desmedt, et al.

"In Vivo Characterization of a Specific Cannabinoid Receptor Antagonist (SR14176A): Inhibition of  $\Delta^9$ -Tetrahydrocannabinol-Induced Responses and Apparent Agonist Activity<sup>1</sup>", David R. Compton, et al.

"The Evaluation of the Analgesic Action of Pethidine Hydrochloride (Demerol)", G. Woolfe, et al.

"Internal Union of Pharmacology, XXVII. Classification of Cannabinoid Receptors", A.C. Howlett, et al.

"Agonist-inverse agonist characterization at CB<sub>1</sub> and CB<sub>2</sub> cannaboid receptors of L759633, L759656 and AM630", Ruth A. Ross, et al.


"One-Pot Synthesis of Trifluoroacetimidoyl Halides", Kenji Tamura

Copies of these references are enclosed together with a Form PTO-1449.

The filing of this Statement is not to be construed as a representation that a search has been made regarding the claimed invention (37 C.F.R. §1.97(g)) or that no other possible material information exists. In addition, the filing of this Information Disclosure Statement is not to be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability (37 C.F.R. §1.97(h)).

The Commissioner is hereby authorized to charge payment for any fees associated with this communication or credit any over payment to Deposit Account No. 16-1350.

Respectfully submitted,

  
\_\_\_\_\_  
Geza C. Ziegler, Jr.  
Reg. No. 44,004

13 October 2004  
Date

PERMAN & GREEN, LLP  
425 Post Road  
Fairfield, CT 068424  
Customer No. 2512



**CERTIFICATE OF MAILING**

I hereby certify that this correspondence is being deposited with the United States Postal Service on the date indicated below as first class mail in an envelope address to the Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: 10/21/04

Signature: *Carolina Rodriguez*  
Person Making Deposit

<b>INFORMATION DISCLOSURE CITATION FORM FOR PATENT APPLICATION (FORM PTO-1449) (Substitute)</b>			Docket No.: 785-011730-US (PAR)      Serial No.: 10/809,534  Applicant(s): CUBERES ALTISEN et al.  Filing Date: 3/19/04      Group:			
<b>U.S. PATENTS</b>						
Initials	Patent Number	Issue Date	Name	Class	Sub-class	Filing date
<b>U.S. PATENT PUBLICATIONS</b>						
Initials	Publication No.	Pub. Date	Name	Class	Sub-class	Filing Date
<b>FOREIGN PATENT DOCUMENTS</b>						
Initials	Document Number	Date	Country	Name	Translation? Yes/No/n/a	
	WO 00/76503 A1	12/21/00	PCT	TEMPLE UNIVERSITY - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION	N/A	
<b>OTHER DOCUMENTS (Title, Author, Date, Pages, Etc., if known)</b>						
	"Health Aspects of Cannabis", Leo E. Hollister, Pharmacological Reviews, 38, 1986, 1-20					
	"Chemistry and Pharmacology of cannabis", Renu Seth, et al., Prog-Drug-Res., 1991, Vol. 36, p. 71-115					
	"Potential Role of Cannabinoids for Therapy of Neurological Disorders", Dewey, W. L., et al., Neurobiology and Neurophysiology, 1992, 459-524					
	"New Way for the Preparation of 4-Phenyl-2-Oxobutyric Acid Ethyl Ester", V. Slavinska, et al., Synthetic Communications, 26 (11), 2229-2233 (1996)					
	"A Straightforward Route to E-γ-Aryl-α-oxobutenoic Esters by One-step Acid-catalysed Crotonisation of Pyruvates", Gilles Dujardin, et al., Synlett 2001, No. 1, 147-149					
	"Synthese des 5-[(Acetylhydrazono)-(4-chlorphenyl)-methyl]thiophen-2-yl-esters der Trifluoromethansulfonsaure", Alfons Pascual, J. Prakt. Chem. 1999, 341, No. 7, 695-699					
	"Regioselective Friedel-Crafts Acylation With Unsymmetrically Substituted Furandicarboxylic Acid Anhydride and Furan Acid Chloride: Syntheses of 4-Substituted 3-Arylcarbonyl-2-Phenylfuran and 3-Substituted 4-Arylcarbonyl-2-Phenylfuran", Shrong-Shi Lin, et al., Heterocycles, Vol. 55, No. 2, 2001, 265-277					
Examiner's Signature:				Date Considered:		
Initial if reference was considered, whether or not citation is in conformance with MPEP. Mark through citation if not considered. Include a copy of this citation form with your next correspondence to the Applicant(s).						

Customer No.: 2512

<b>INFORMATION DISCLOSURE CITATION FORM FOR PATENT APPLICATION (FORM PTO-1449) (Substitute)</b>			Docket No.: 785-011730-US (PAR)      Serial No.: 10/809,534  Applicant(s): CUBERES ALTISEN et al.  Filing Date: 3/19/04      Group:			
<b>U.S. PATENTS</b>						
Initials	Patent Number	Issue Date	Name	Class	Sub-class	Filing date
<b>U.S. PATENT PUBLICATIONS</b>						
Initials	Publication No.	Pub. Date	Name	Class	Sub-class	Filing Date
<b>FOREIGN PATENT DOCUMENTS</b>						
Initials	Document Number	Date	Country	Name	Translation? Yes/No/n/a	
<b>OTHER DOCUMENTS (Title, Author, Date, Pages, Etc., if known)</b>						
	"Friedel-Crafts Acylations with Little or No Catalyst", D.E. Pearson, et al., Synthesis, 1972, 533-542					
	"Rational Synthesis of Porphyrins Bearing up to Four Different Meso Substituents", Polisetti Dharma Rao, et al., J. Org. Chem. 2000, 65, 7323-7344					
	"Pharmacological Effects of Hoe 249: A New Potential Antidepressant", Hans Georg Alpermann, et al., Drug Development Research 25:267-282 (1992)					
	"Anticonvulsive Properties of Cinnarizine and Flunarizine in Rats and Mice", L.K.C. Desmedt, et al., Arzneim-Forsch. (Drug Res.) 25, Nr. 9 (1975)1408-1413					
	"In Vivo Characterization of a Specific Cannabinoid Receptor Antagonist (SR141716A): Inhibition of $\Delta^9$ -Tetrahydrocannabinol-Induced Responses and Apparent Agonist Activity", David R. Compton, et al., The Journal of Pharmacology and Experimental Therapeutics, Vol. 277, No. 2, 586-594					
	"The Evaluation of The Analgesic Action of Pethidine Hydrochloride (Demerol)", G. Woolfe, et al., J. Pharm. Exp. Ther., 80, 300-307 (1.944), 300-307					
	"International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors", A.C. Howlett, et al., Pharmacological Reviews, Vol. 54, No. 2, 2002, 161-202					
	"Agonist-inverse agonist characterization at CB <sub>1</sub> and CB <sub>2</sub> cannabinoid receptors of L759633, L759656 and AM630", Ruth A. Ross, et al., British Journal of Pharmacology (1999) 126, 665-672					
	"One-Pot Synthesis of Trifluoroacetimidoyl Halides", Kenji Tamura, et al., J. Org. Chem. 1993, 58, 32-38					
Examiner's Signature:				Date Considered:		
Initial if reference was considered, whether or not citation is in conformance with MPEP. Mark through citation if not considered. Include a copy of this citation form with your next correspondence to the Applicant(s).						

Customer No.: 2512